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Background: The escalating use of prescribed drugs has increasingly raised concerns about polypharmacy. This
study aims to examine changes in rates of polypharmacy and potentially serious drug-drug interactions in a stable
geographical population between 1995 and 2010.
Methods: This is a repeated cross-sectional analysis of community-dispensed prescribing data for all 310,000
adults resident in the Tayside region of Scotland in 1995 and 2010. The number of drug classes dispensed and the
number of potentially serious drug-drug interactions (DDIs) in the previous 84 days were calculated, and age-sex
standardised rates in 1995 and 2010 compared. Patient characteristics associated with receipt of ≥10 drugs
and with the presence of one or more DDIs were examined using multilevel logistic regression to account for
clustering of patients within primary care practices.
Results: Between 1995 and 2010, the proportion of adults dispensed ≥5 drugs doubled to 20.8%, and the
proportion dispensed ≥10 tripled to 5.8%. Receipt of ≥10 drugs was strongly associated with increasing age
(20–29 years, 0.3%; ≥80 years, 24.0%; adjusted OR, 118.3; 95% CI, 99.5–140.7) but was also independently more
common in people living in more deprived areas (adjusted OR most vs. least deprived quintile, 2.36; 95% CI,
2.22–2.51), and in people resident in a care home (adjusted OR, 2.88; 95% CI, 2.65–3.13). The proportion with
potentially serious drug-drug interactions more than doubled to 13% of adults in 2010, and the number of drugs
dispensed was the characteristic most strongly associated with this (10.9% if dispensed 2–4 drugs vs. 80.8% if
dispensed ≥15 drugs; adjusted OR, 26.8; 95% CI 24.5–29.3).
Conclusions: Drug regimens are increasingly complex and potentially harmful, and people with polypharmacy
need regular review and prescribing optimisation. Research is needed to better understand the impact of multiple
interacting drugs as used in real-world practice and to evaluate the effect of medicine optimisation interventions
on quality of life and mortality.
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Prescribed drugs significantly improve a range of health
outcomes, but also cause considerable harm. Approxi-
mately 6.5% of all emergency hospital admissions are at-
tributable to adverse drug events (ADEs), and at least half
of these are judged preventable [1,2]. ADEs have become
more common both as a cause of hospital admission [3]* Correspondence: b.guthrie@dundee.ac.uk
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unless otherwise stated.and as the reason for outpatient and emergency room
visits [4]. ADEs and serious harms occur at all ages, al-
though they are commoner in older people, who are more
vulnerable to drug toxicity because of age-related changes
in pharmacokinetics and pharmacodynamics, because of
multimorbidity and frailty, and because of polypharmacy
[4-7]. Polypharmacy is usually defined as concomitant
prescription of ≥5 or ≥10 drugs (the latter sometimes
called ‘major’ or ‘excessive’ polypharmacy), and there is
some evidence of rising rates of polypharmacy, potentially. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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outpatient and inpatient settings [3,4,8,9].
The appropriate number of drugs for an individual
is highly variable depending on the conditions they
have and their functional status, life expectancy, and
preferences [10,11]. Among older people taking multiple
drugs, there is often evidence of simultaneous over- and
under-treatment, with prescribers and patients often
struggling to balance benefit and harm in the face of
complexity and uncertainty [11]. This partly reflects that
evidence of benefit is often derived from trials that usu-
ally exclude older adults and people with multimorbidity
and do not quantify harms well [12-15], and partly that
guidelines often recommend chronic treatments with
benefits that are only evident over long periods without
explicitly addressing relevance to people with shorter life
expectancy [16-18]. Other factors further complicate
predicting the benefit/harm of drug treatment, including
our limited understanding of ADEs and interactions in
people taking large numbers of drugs and the difficulty
of distinguishing ADEs from symptoms of existing con-
ditions, risking a ‘prescribing cascade’ where more drugs
are used to treat ADEs from existing drugs [6]. Poly-
pharmacy is consistently associated with higher rates of
potentially serious DDIs and ADEs, although the in-
creasing use of electronic prescribing with automatic
interaction detection might be expected to have reduced
this risk over time [4,8,9,19-22]. Although polypharmacy
is not always inappropriate, it is frequently problematic,
and managing people with multimorbidity and polyphar-
macy is an important challenge for clinicians and health
systems worldwide [5,17]. Of note, although the litera-
ture in relation to polypharmacy focuses on older
people, polypharmacy is largely driven by multimorbidity
and a significant proportion of people with multimorbid-
ity are aged less than 65 years, particularly in the most
socioeconomically deprived populations where multi-
morbidity on average occurs 10 to 15 years earlier than
in the most affluent populations [5].
Few studies have used population data to examine
changes in polypharmacy and the risk of potentially ser-
ious DDIs over time [4,9]. The aim of this study was to
use data for all ~310,000 adults resident in a defined
geographical area to examine how the prevalence of
polypharmacy and potentially serious DDIs changed be-
tween 1995 and 2010, and to examine patient and prac-
tice characteristics associated with polypharmacy or the
presence of a potentially serious DDI in 2010.
Methods
Dataset
Prescribing and demographic data were obtained from
the University of Dundee Health Informatics Centre
(HIC) for all people aged ≥20 years resident in theTayside region of Scotland for at least 1 year and regis-
tered with a National Health Service (NHS) general
practitioner (GP) in NHS Tayside on either 31st March
1995 or 31st March 2010. Registration with a single gen-
eral practice is required to obtain UK NHS care, and
with the exception of a few highly specialised drugs,
such as biological treatments for inflammatory arthritis,
GPs are responsible for all community prescribing to pa-
tients. Since the 1990s, HIC has collected data on pre-
scriptions dispensed to Tayside residents by community
pharmacies since the 1990s, and these can be linked to
each other, using the NHS Scotland unique identifiers
(the Community Health Index number) to create a
patient-level prescribing record, and to other datasets.
For included patients, data on all NHS dispensed pre-
scriptions in the previous 84 days were obtained from a
validated research dataset which creates patient-level
prescribing records by linking prescriptions using the
NHS Scotland unique identifier (the Community Health
Index number). We included prescriptions dispensed in
the previous 84 days because the most common length
of prescription for chronically prescribed drugs is 56 days
(usual range 28–84 days), but since patients will not al-
ways request repeat prescriptions at precisely the same
interval as the prescription length, an 84-day window
is the most reliable measure of current exposure. Demo-
graphic data available included age, gender, socioeco-
nomic status (measured by the Scottish Index of Multiple
Deprivation [23]), and residence in a nursing home (avail-
able for 2010 only). Data linkage and anonymization was
carried out under HIC Standard Operating Procedures
which have been approved by the NHS Research Ethics
Service, and all analysis was conducted on anonymised
data in the HIC secure Safe Haven. The study was ap-
proved by the NHS Tayside Caldicott Guardian, and indi-
vidual study approval by the NHS Research Ethics Service
was therefore not required.
Defining polypharmacy
We counted the presence of distinct drug classes dis-
pensed in the previous 84 days, which is one of the
standard ways of measuring polypharmacy in routine
data, giving similar results to other methods [24]. De-
vices which do not actually deliver drugs (such as blood
glucose monitoring equipment), dressings, stoma, or
urinary catheter-related products and vaccines were ex-
cluded. Drug classes were defined in terms of subsec-
tions of the British National Formulary (BNF) [25],
which typically contain a single class of agent with simi-
lar mechanisms of action (for example, BNF 2.4 corre-
sponds to beta-adrenoreceptor blocking drugs). We
expanded the BNF classification where BNF subsections
contain multiple drugs which are distinct and commonly
co-prescribed (for example, BNF 2.9 antiplatelet drugs
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clopidogrel, and so on). The constituents of combination
products were separately counted. The complete list of
included drug classes is provided in the Additional file 1.
We defined three levels of polypharmacy as ≥5, ≥10, and
≥15 drugs dispensed in the previous 84 days.
Defining potentially serious drug-drug interactions (DDIs)
We examined the frequency of DDIs, defined as co-
prescription within the 84-day period on or before 31st
March 1995 or 31st March 2010 of pairs of drugs that
were listed as having ‘potentially serious’ DDIs (where
co-prescription is to be “avoided or only undertaken with
caution and appropriate monitoring”) in the March 2010
edition of the BNF [25]. In the paper version of the BNF,
these interactions are emphasised to prescribers by flagging
them with a ‘black dot’, and in the online version by colour
coding them red. Of note, we can only measure that a pre-
scription was dispensed, and cannot know whether the pa-
tient actually took both drugs simultaneously. However, the
measure used is consistent in both years so is reasonable to
estimate changes in potential risk. We used the 2010 BNF
to define the presence of potentially serious interactions so
that the measures were the same in both years.
Statistical methods
We calculated changes in the number of drugs dis-
pensed and the number of potentially serious interac-
tions experienced, both in total and in terms of the BNF
chapter that drugs were listed under. The statistical sig-
nificance of any differences between 1995 and 2010 were
evaluated, using directly age-sex standardised propor-
tions for 2010 to account for the ageing of the popula-
tion between 1995 and 2010. For 2010, the correlation
between patient and general practice characteristics as-
sociated with the dispensing of 10 or more drugs and
with the presence of any interaction were examined
using multilevel modelling to account for the clustering
of patients within practices. To assess the extent to
which variation in each outcome was attributable to
variation between practices, the intra-class correlation
co-efficient was estimated in empty models. Data man-
agement and analysis were carried out in IBM PASW
v21 (IBM Corporation 2012) and multilevel modelling in
StataIC v11 (StataCorp 2012). The study was conducted
as part of Chief Scientist Office Applied Research
Programme Grant ARPG 07/2. The funder had no role
in the study design, analysis, or the decision to publish.
Results
Study population
There were 301,019 people aged ≥20 years resident in
the region in 1995, with a mean age of 48.4 years, rising
to 311,811 in 2010, with a mean age of 50.1 years(difference 1.7 years, t = 37.1, P <0.001). The proportion
of residents aged ≥70 years rose from 15.7% in 1995 to
17.0% in 2010 (difference, 1.3%; 95% confidence interval
(CI), 1.1–1.4) but the proportion who were female did
not change significantly (51.7% in 1995, 51.5% in 2010,
difference 0.2%; 95% CI, 0–0.5).
Changes in the prevalence of polypharmacy between
1995 and 2010
In 1995, 151,191 (50.6%) people were dispensed one or
more drugs in the previous 84 days, compared to 183,726
(58.9%) in 2010 (difference, 8.2%; 95% CI, 8.0–8.4; Table 1),
with only a small part of the difference accounted for by
population aging (57.8% directly age-sex standardised
prevalence in 2010). Between 1995 and 2010, the propor-
tion of people dispensed 5 to 9 drugs rose from 9.7% to
16.3%, dispensed 10 to 14 drugs from 1.5% to 4.7%, and
dispensed 15 or more drugs from 0.2% to 1.1% (age-sex
standardised relative risks 1.57, 2.92, and 5.58, respect-
ively; Table 1). Drug use in both years was strongly associ-
ated with age, with a steady increase in the number of
drugs dispensed from early adulthood rising more steeply
from middle age (Figure 1). The proportion of people aged
65 and over who were dispensed 10 or more drugs more
than tripled between 1995 (4.9%) and 2010 (17.2%).
Drug groups associated with changes in polypharmacy
between 1995 and 2010
The proportion of people dispensed drugs from each
BNF chapter rose significantly for every chapter except
drugs for infections and musculoskeletal drugs, where
use fell slightly (Table 1). The largest absolute rises were
for cardiovascular (27.3% of the population in 2010 vs.
16.8% in 1995; age-sex standardised relative risk [sRR],
1.49), central nervous system (26.3% vs. 18.6%; sRR,
1.37), gastrointestinal (18.1% vs. 12.6%; sRR, 1.36), and
endocrine drugs (14.3% vs. 8.8%, sRR, 1.53). The number
of BNF chapters that patients were dispensed drugs from
increased, with 10,917 (3.6%) patients dispensed drugs
from five or more chapters in 1995 compared to 23,887
(7.7%) in 2010 (sRR, 1.97).
Patient and practice characteristics associated with
polypharmacy in 2010
In multilevel modelling, age was the patient characteris-
tic most strongly associated with dispensing of ≥10
drugs rising from 0.3% of those aged 20 to 29 years to
22.9% of those aged ≥80 (adjusted OR [aOR], 118.3; 95%
CI, 99.5–140.7) (Table 2). People living in care homes
were much more likely to be dispensed ≥10 drugs in
univariate analysis (36.5% vs. 5.5% of those living at
home), although the association between care home resi-
dency and polypharmacy was greatly reduced in the ad-
justed model reflecting that care home residents are
Table 1 Numbers and class of drugs dispensed to adults in 1995 and 2010
1995 2010 2010
No. (%) of patients
n = 301,019
No. (%) of patients
n = 311,881
Age-sex
standardised %*
Age-sex
standardised
relative risk
2010 vs. 1995
(95% CI)
Dispensed 0 drugs 148,828 (49.4) 128,155 (41.1) 42.8 0.87 (0.86–0.87)
Dispensed 1–4 drugs 117,829 (39.1) 114,540 (36.7) 36.4 0.93 (0.92–0.94)
Dispensed 5–9 drugs 29,311 (9.7) 50,972 (16.3) 15.3 1.57 (1.55–1.60)
Dispensed 10–14 drugs 4,481 (1.5) 14,662 (4.7) 4.4 2.92 (2.83–3.02)
Dispensed ≥15 drugs 570 (0.2) 3,552 (1.1) 1.1 5.58 (5.11–6.10)
Dispensed any drug from BNF chapter
1 (gastrointestinal) 37,813 (12.6) 56,536 (18.1) 17.1 1.36 (1.35–1.38)
2 (cardiovascular) 50,593 (16.8) 85,140 (27.3) 25.2 1.49 (1.48–1.51)
3 (respiratory) 18,368 (6.1) 24,760 (7.9) 7.7 1.26 (1.24–1.28)
4 (central nervous system) 55,920 (18.6) 81,902 (26.3) 25.4 1.37 (1.36–1.38)
5 (infections) 48,610 (16.1) 46,934 (15.0) 14.8 0.92 (0.90–0.93)
6 (endocrine) 26,469 (8.8) 44,695 (14.3) 13.5 1.53 (1.51–1.55)
7 (O&G, and urinary tract) 11,695 (3.9) 23,126 (7.4) 7.4 1.91 (1.87–1.95)
8 (malignancy, immunosuppression) 1,686 (0.6) 3,062 (1.0) 0.9 1.64 (1.54–1.74)
9 (nutrition and blood) 8,634 (2.9) 15,217 (4.9) 4.7 1.62 (1.58–1.67)
10 (musculoskeletal) 26,166 (8.7) 26,185 (8.4) 8.0 0.92 (0.91–0.94)
11 (eye) 8,166 (2.7) 11,726 (3.8) 3.5 1.30 (1.27–1.34)
12 (ear, nose, and throat) 8,633 (2.9) 12,459 (4.0) 3.8 1.34 (1.30–1.37)
13 (skin) 23,345 (7.8) 31,644 (10.1) 9.9 1.28 (1.26–1.30)
Number of BNF chapters dispensed drugs from
0 148,828 (49.4) 128,155 (41.1) 42.8 0.87 (0.86–0.87)
1 65,584 (21.8) 64,625 (20.7) 20.7 0.95 (0.94–0.96)
2 40,561 (13.5) 45,439 (14.6) 14.2 1.05 (1.04–1.07)
3 22,548 (7.5) 30,129 (9.7) 9.2 1.23 (1.21–1.25)
4 12,581 (4.2) 19,646 (6.3) 5.9 1.42 (1.39–1.45)
5+ 10,917 (3.6) 23,887 (7.7) 7.1 1.97 (1.92–2.01)
*2010 data directly age-sex standardised to 1995 population structure.
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After adjustment, people living in more deprived areas
had over twice the odds of being dispensed ≥10 drugs.
Women were slightly more likely to have polypharmacy
than men, as were people living in urban compared to
more rural areas. Variation between practices was mod-
est, with an intra-class correlation coefficient of 0.009 in
the empty model (interpretable as 0.9% of the variation
in outcomes being due to variation between practices).
None of the practice characteristics examined were sig-
nificantly associated with dispensing of ≥10 drugs.
Changes in potentially serious DDIs between 1995 and 2010
Potentially serious DDIs were over twice as common in
2010 than 1995, with 5.8% of adults in 1995 having atleast one DDI compared to 13.1% in 2010 (sRR, 2.08;
95% CI, 2.04–2.12; Table 3). There were larger relative
increases in the proportion of the population with mul-
tiple potentially serious DDIs; for example, the propor-
tion with ≥2 DDIs more than tripling from 1.5% of
adults in 1995 to 5.6% in 2010. In both years, older
people were more likely to have a potentially serious
DDI (Figure 2, Table 4), with 10,272 (15.2%) of people
aged ≥65 having at least one in 1995 compared to
25,071 (34.1%) in 2010.
Drug groups associated with changes in potentially
serious DDIs between 1995 and 2010
Table 3 shows that the drug groups most commonly
implicated in potentially serious DDIs in 1995 were
Figure 1 Number of drug classes dispensed in the 84-day period in 1995 and 2010 by age of patient.
Guthrie et al. BMC Medicine  (2015) 13:74 Page 5 of 10cardiovascular (affecting 4.7% of adults), central nervous
system (1.2%), and musculoskeletal (0.9%) drugs. These
remained the three drug groups most implicated in
2010, but with significantly increased prevalence (10.9%,
3.7%, and 1.5%, respectively; sRR, 2.09, 2.93, and 1.64).
There were larger relative but smaller absolute increases
in interactions associated with obstetric and gynaeco-
logical drugs (from 0.09% to 0.81%; sRR, 7.66) and
gastrointestinal drugs (from 0.07% to 0.47%; sRR, 6.30).
Other drug groups changed more variably, althoughabsolute rates were low in 1995 and absolute differences
between years were much smaller.
Patient and practice characteristics associated with DDIs
in 2010
In multilevel modelling, the number of drugs dispensed
was the characteristic most strongly associated with the
presence of a potentially serious DDI among people dis-
pensed at least 2 drugs (the minimum number required
for a DDI to be present). The proportion of people with
Table 2 Patient characteristics associated with dispensing of ≥10 drugs in 2010*
Variable (no. of patients) Proportion (95% CI)
dispensed ≥10 drugs
Univariate multilevel
odds ratio (95% CI)
Adjusted multilevel
odds ratio (95% CI)
Age groups (years)
20–29 (n = 51,197) 0.3 (0.2–0.3) Reference Reference
30–39 (n = 47,857) 0.7 (0.6–0.8) 2.81 (2.31–3.41) 2.91 (2.38–3.56)
40–49 (n = 60,077) 1.7 (1.5–2.0) 6.78 (5.69–8.09) 7.16 (5.98–8.58)
50–59 (n = 52,751) 4.1 (3.6–4.6) 16.9 (14.2–20.0) 18.0 (15.1–21.5)
60–69 (n = 47,080) 8.7 (7.9–9.4) 38.1 (32.2–45.2) 41.1 (34.6–48.8)
70–79 (n = 32,986) 17.1 (16.1–18.2) 83.4 (70.5–98.7) 87.5 (73.7–104.0)
80+ (n = 19,933) 24.0 (22.9–25.1) 130.0 (10.9.8–153.9) 118.3 (99.5–140.7)
Sex
Male (n = 151,202) 4.6 (4.3–4.8) Reference Reference
Female (n = 160,679) 7.0 (6.7–7.4) 1.59 (1.54–1.64) 1.34 (1.30–1.39)
Deprivation quintile
1 (affluent) (n = 56,416) 4.9 (4.5–5.4) Reference Reference
2 (n = 94,090) 5.3 (5.0–5.7) 1.13 (1.07–1.19) 1.21 (1.14–1.28)
3 (n = 53,990) 5.3 (5.0–5.6) 1.04 (0.99–1.10) 1.32 (1.24–1.39)
4 (n = 49,387) 6.4 (6.0–6.7) 1.33 (1.26–1.40) 1.70 (1.61–1.79)
5 (deprived) (n = 50,877) 7.6 (7.1–8.1) 1.58 (1.49–1.67) 2.36 (2.22–2.51)
SEURC category#
Primary city (n = 121,804) 6.5 (6.1–6.9) Reference Reference
Urban area (n = 80,401) 6.0 (5.5–6.5) 0.91 (0.84–1.00) 0.96 (0.88–1.05)
Accessible area (n = 78,490) 5.0 (4.6–5.4) 0.74 (0.69–0.80) 0.84 (0.78–0.92)
Remote area (n = 24,268) 5.7 (5.0–6.3) 0.85 (0.75–0.96) 0.83 (0.73–0.94)
Living
In own home (n = 308,660) 5.5 (5.2–5.8) Reference Reference
In care home (n = 3,221) 36.5 (33.8–39.1) 9.91 (9.21–10.67) 2.88 (2.65–3.13)
*Practice level variables not significant in either univariate or adjusted models (list size, accreditation for postgraduate training, dispensing medicines [marginally
significant association in univariate analysis], type of NHS contract).
#Scottish Executive Urban–rural Classification.
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pensed ≥15 drugs compared to 10.9% of those dispensed
2 to 4 drugs (aOR, 26.8; 95% CI, 24.5–29.3). Older
people were also much more likely to be prescribed
drugs with an interaction, as were men to a small extent.
The strength of the association between older age and
presence of DDIs was significantly weakened after ad-
justment for numbers of drugs dispensed (reflecting
much higher rates of drug use in the elderly), but people
aged 80 and over were still much more likely to have
DDIs, with an adjusted odds ratio of 7.34 (95% CI, 6.62–
8.14) compared to 20 to 29 year olds. In contrast, after
adjustment for age and the number of drugs dispensed,
people in care homes were less likely to be dispensed
interacting drugs. There was more variation between
practices for prescribing drugs with potentially serious
interactions than there was for polypharmacy, with an
intra-class correlation coefficient in the empty model
of 0.031. However, none of the practice characteristicsexamined were significantly associated with potentially
serious DDIs.
Discussion
Between 1995 and 2010 there were large increases in the
number of patients with polypharmacy due to an in-
crease in the use of drugs from all but two BNF chap-
ters. The dispensing of ≥5 drugs increased from 11.4%
to 20.8% of adults, and the dispensing of ≥10 drugs in-
creased from 1.7% to 5.8%. Receipt of ≥10 drugs was
very strongly associated with increasing age, but was also
independently more common in women, in people living
in more deprived areas, and in care home residents. As-
sociated with this, the proportion of adults with poten-
tially serious DDIs more than doubled, with 13.0% of
adults in 2010 being dispensed a combination of drugs
with the potential to cause serious harm. Interactions in-
creased in prevalence dramatically with the number of
drugs dispensed, rising from 10.9% in those dispensed 2
Table 3 Potentially serious drug-drug interactions in 1995 and 2010
1995 2010 2010
No. (%) of
patients
No. (%) of
patients
Age-sex standardised
% of patients*
Age-sex
standardised
relative risk
2010 vs. 1995
(95% CI)
n = 301,019 n = 311,881 n = 311,881
All patients 17,448 (5.8) 40,689 (13.0) 12.1 2.08 (2.04–2.12)
No. of interactions
0 283,571 (94.2) 271,192 (86.9) 87.9 0.91 (0.91–0.91)
1 13,051 (4.3) 23,907 (7.7) 7.1 2.41 (2.35–2.47)
2 3,151 (1.0) 9,324 (3.0) 2.8 5.54 (5.25–5.85)
3 814 (0.3) 3,776 (1.2) 1.1 7.03 (6.39–7.74)
4+ 432 (0.1) 3,682 (1.2) 1.1 13.8 (12.1–15.7)
Any interaction involving drugs from BNF chapter
1 (gastrointestinal) 197 (0.07) 1,452 (0.47) 0.42 6.30 (5.44–7.31)
2 (cardiovascular) 14,236 (4.7) 34,124 (10.9) 9.9 2.09 (2.05–2.13)
3 (respiratory) 863 (0.30) 863 (0.28) 0.26 0.84 (0.77–0.93)
4 (central nervous system) 3,489 (1.2) 11,465 (3.7) 3.4 2.93 (2.81–3.04)
5 (infections) 1,062 (0.37) 1,526 (0.49) 0.45 1.22 (1.13–1.32)
6 (endocrine) 688 (0.23) 1,588 (0.51) 0.47 2.00 (1.83–2.19)
7 (O&G, and urinary tract) 257 (0.09) 2,516 (0.81) 0.68 7.66 (6.75–8.69)
8 (malignancy, immunosuppression) 125 (0.04) 207 (0.07) 0.06 1.44 (1.15–1.79)
9 (nutrition and blood) 252 (0.09) 62 (0.02) 0.02 0.22 (0.16–0.29)
10 (musculoskeletal) 2,565 (0.87) 4,717 (1.5) 1.4 1.64 (1.56–1.72)
11 (eye) 21 (0.01) 9 (0.003) 0.003 0.38 (0.17–0.82)
12 (ear, nose, and throat) 0 0 0 –
13 (skin) 0 0 0 –
*2010 data directly age-sex standardised to 1995 population structure.
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was also strongly associated with being dispensed inter-
acting drugs, and this association persisted (albeit
weaker) after adjusting for the number of drugs an indi-
vidual was dispensed. Interestingly, although men were
less likely to be prescribed large numbers of drugs, they
were more likely to be dispensed interacting drugs.
These population-based results are similar to the lim-
ited published research in more selective populations. In
a representative survey of adults aged ≥77 years in
Sweden, Haider et al. showed that the percentage pre-
scribed ≥5 drugs rose from 18% in 1992 to 42% in 2002,
with an increase from 17% to 25% of older people ex-
posed to a potentially serious DDI [9]. Between 2000
and 2010 in Italy, the proportion of people aged
≥65 years prescribed five or more active agents rose
from 43% to 53%, with larger rises in those aged
≥85 years [26]. In the USA, the proportion of outpatient
consultations in which patients were taking 5 or more
medications rose from 6% to 15% between 1995 and
2005, and the rate of outpatient or emergency roomconsultations where an ADE was reported rose from
13.2 per 1,000 persons to 18.1 per 1,000 persons, with
ADE rates increasing with the number of drugs a patient
was taking [4]. Swedish and Italian data also show a
strong relationship between numbers of drugs dispensed
and potentially serious DDIs [8,19].
A key strength of the study is the use of dispensed
prescribing data for a defined geographical population
collected using the same method, but all data of this sort
has several limitations. Over-the-counter sales are not
accounted for, which is important for drugs such as
analgesics (paracetamol, selected non-steroidal anti-
inflammatory drugs, and low dose codeine), simple ant-
acids, and antihistamines, as well as non-prescribed
products with potential for interactions such as St John’s
Wort. Actual drug use and interactions will therefore
be underestimated in both years. In contrast, interac-
tions are likely to be somewhat overestimated by our
counting co-prescription in an 84-day period as indicat-
ing the presence of an interaction since, in some cases,
patients will have stopped one drug before starting
Figure 2 Number of potentially serious drug-drug interactions in the 84-day period in 1995 and 2010 by age of patients.
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two years and is therefore a reasonable estimate of the
scale of the change in risk. The interactions being
counted are also potentially, rather than always, harmful,
and most interactions will not cause harm, although
much harm is also unrecognised by clinicians. However,
since measurement is consistent over the period exam-
ined, we believe that the patterns of change seen will
plausibly reflect changes in harm as well. The maininteraction comparison also applies 2010 knowledge to
both years, which effectively penalises prescribers in
1995 since the measure includes interactions which they
could not be aware of. However, this is likely to make
the change observed a conservative estimate and it is
worth noting that the estimate of the potential inter-
action rate in 2010 is itself an underestimate since
knowledge continues to evolve (a recent example being
the 2012 UK regulatory risk communication concerning
Table 4 Patient characteristics associated with the presence of a potentially serious drug-drug interaction for people
dispensed at least two drugs in 2010
Variable (no. of patients) Proportion (95% CI)
with any DDI
Univariate multilevel
odds ratio (95% CI)
Adjusted multilevel
odds ratio (95% CI)
Age groups (years)
20–29 (n = 9,976) 4.5 (4.0–5.0) Reference Reference
30–39 (n = 12,294) 9.2 (8.6–9.8) 2.18 (1.5–2.44) 1.88 (1.68–2.11)
40–49 (n = 18,805) 15.8 (14.9–16.6) 4.05 (3.65–4.49) 3.05 (2.75–3.39)
50–59 (n = 23,565) 25.1 (24.0–26.2) 7.28 (6.59–8.04) 4.67 (4.21–5.17)
60–69 (n = 30,756) 33.8 (32.8–34.8) 11.2 (10.1–12.3) 6.05 (5.47–6.69)
70–79 (n = 27,240) 42.5 (41.4–43.6) 16.2 (14.7–17.9) 6.98 (6.31–7.72)
80+ (n = 17,977) 46.0 (44.8–47.1) 18.8 (17.0–20.7) 7.34 (6.62–8.14)
Sex
Male (n = 58,466) 30.7 (30.0–31.5) Reference Reference
Female (n = 82,147) 27.7 (27.0–28.4) 0.87 (0.85–0.88) 0.85 (0.83–0.88)
Place of residence
Living in own home (n = 13,615) 28.7 (28.1–29.4) Reference Reference
Living in care home (n = 2,998) 38.0 (36.3–39.7) 1.51 (1.40–1.63) 0.51 (0.47–0.56)
No. of drugs dispensed in last 84 days
2–4 (n = 71,427) 10.9 (10.4–11.4) Reference Reference
5–9 (n = 50,972) 40.0 (39.0–40.9) 5.49 (5.33–5.65) 4.39 (4.26–4.53)
10–14 (n = 14,662) 65.9 (64.9–67.0) 16.1 (15.5–16.8) 12.0 (11.5–12.5)
15+ (n = 3,552) 80.8 (79.4–82.2) 35.3 (32.3–38.5) 26.8 (24.5–29.3)
Patient level socioeconomic deprivation and urban/rural residence, and practice level variables (list size, accreditation for postgraduate training, dispensing
medicines, type of NHS contract) were not significant in either univariate or adjusted models and are not shown.
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with calcium-channel antagonists, which on its own
would have affected 2.4% of Tayside adults in 2010) [27].Conclusions
Although this study cannot identify which is most import-
ant, there are several reasons why rates of prescribing are
likely to have risen, including the greater availability of ef-
fective drugs, the promotion of consistent treatment of
many chronic conditions by guidelines and other quality
improvement interventions, and changes in patient expec-
tations. Of particular note is that guidelines increasingly
recommend multiple drug therapy to achieve tight inter-
mediate outcomes such as blood pressure and glycaemic
control. This highlights that polypharmacy is potentially
problematic rather than always inappropriate, because po-
tentially serious interactions do not always cause harm or
may be a price worth paying for benefits. However, most
evidence of effectiveness is from randomised trials which
usually exclude older people and those with multimorbid-
ity and polypharmacy [17]. Our understanding of the
benefits of real-world complex treatment regimens is
therefore limited, and our understanding of harms largely
restricted to pairwise interactions rather than the often
more complex reality.The key clinical implication is that clinicians need
to regularly review and optimise chronic medication,
particularly in people with polypharmacy or whose life
expectancy is limited to a few years in whom drugs for
prevention are less likely to be beneficial. Since poly-
pharmacy almost inevitably involves drugs for multiple
conditions, medication reviews will typically have to be
the responsibility of generalist physicians or pharmacists,
who require appropriate training in how to personalise
treatment in people with multimorbidity or frailty in order
to minimise harm while retaining drugs with large benefit
[5]. Clinical guidelines also need to consider making
recommendations on when drugs should be stopped, al-
though the lack of discussion in guidelines about treat-
ment cessation at least partly reflects the lack of evidence
in this area [16-18]. There is therefore a need for research
to evaluate the impact of treatment cessation in frailer
people with shorter life expectancy, focusing on drugs
with small prognostic benefits that accrue over long pe-
riods of time. Further research is needed to improve our
understanding of the risks and benefits of the complex
combinations of potentially interacting drugs that happen
in the real world, and for trials of interventions to opti-
mise treatment of people with polypharmacy, which evalu-
ate the impact on mortality and quality of life as well as
prescribing outcomes [28].
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